Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs

Drug and Alcohol Review

Volumn 24, Issue 1, 2005, Pages 39-48

  Hall, Wayne D ^a,b   Lynskey, Michael ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Causal explanations of cannabis use; Drug use patterns; Gateway hypothesis

Indexed keywords

STREET DRUG;

ADDICTION; ADOLESCENT; CANNABIS ADDICTION; HUMAN; REVIEW; SOCIAL ENVIRONMENT;

ADOLESCENT; HUMANS; MARIJUANA ABUSE; SOCIAL ENVIRONMENT; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 22944470171     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230500126698     Document Type: Review

References (66)

1. Kandel DB, ed. Stages and pathways of drug involvement: examining the gateway hypothesis. New York: Cambridge University Press, 2002.
2. DuPont RL. Getting tough on gateway drugs: a guide for the family. Washington, DC: American Psychiatric Press, 1984.
3. Polich JM, Ellickson PL, Reuter P, Kahan JP. Strategies for controlling adolescent drug use. Santa Monica, CA: Rand Corporation, 1984.
4. de Kort M, Cramer T. Pragmatism versus ideology: Dutch drug policy continued. J Drug Issues 1999;29(3):473-492.
5. Morral AR, McCaffrey DF, Paddock SM. Reassessing the marijuana gateway effect. Addiction 2002;97(12):1493-504.
6. Kandel D. Stages in adolescent involvement in drug use. Science 1975;190:912-914.
7. Golub A, Johnson BD. Substance use progression and hard drug use in inner-city New York. In: Kandel DB, ed. Stages and pathways of drug involvement: examining the gateway hypothesis. Cambridge, UK: Cambridge University Press, 2002:p. 90-112.
8. Kandel DB. Marijuana users in young adulthood. Arch Gen Psychiatry 1984;41(2):200-9.
9. Donnelly N, Hall WD. Patterns of cannabis use in Australia. Canberra: Australian Government Publishing Service, 1994.
10. Donovan JE, Jessor R. Problem drinking and the dimension of involvement with drugs: a Guttman scalogram analysis of adolescent drug use. Am J Public Health 1983;73(5):543-52.
11. Kandel DB. Issues of sequencing of adolescent drug use and other problem behaviors. Drugs Soc 1988;3(1-2):55-76.
12. Kandel DB. Convergences in prospective longitudinal surveys of drug use in normal populations. In: Kandel DB, ed. Longitudinal research on drug use: empirical findings and methodological issues. New York: John Wiley, 1978:p. 3-38.
13. Robins L, Darvish HS, Murphy GE. The long-term outcome for adolescent drug users: a follow-up study of 76 users and 146 nonusers. In: Zubin J, Freedman AM, eds. The psychopathology of adolescence. New York: Grune and Stratton, 1970.
14. Kandel DB, Davies M, Karus D, Yamaguchi K. The consequences in young adulthood of adolescent drug involvement: an overview. Arch Gen Psychiatry 1986;43(8):746-754.
15. Kandel DB, Yamaguchi K. Stages of drug involvement in the U.S. population. In: Kandel DB, ed. Stages and pathways of drug involvement: examining the gateway hypothesis. New York: Cambridge University Press, 2002:p. 65-89.
16. Kaplan HB, Martin SS, Robbins C. Pathways to adolescent drug use: self-derogation, peer influence, weakening of social controls, and early substance use. J Health Soc Behav 1984;25(3):270-289.
17. Yamaguchi K, Kandel DB. Patterns of drug use from adolescence to young adulthood: III. Predictors of progression. Am J Public Health 1984;74(7):673-81.
18. Yamaguchi K, Kandel DB. Patterns of drug use from adolescence to young adulthood: II. Sequences of progression. Am J Public Health 1984;74(7):668-72.
19. Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 1997;92(3):279-296.
20. Fergusson DM, Horwood LJ. Prospective childhood predictors of deviant peer affiliations in adolescence. J Child Psychol Psychiatry 1999;40(4):581-592.
21. Fergusson DM, Horwood LJ. Does cannabis use encourage other forms of illicit drug use? Addiction 2000;95(4):505-520.
22. McGee R, Feehan M. Cannabis use among New Zealand adolescents. N Z Med J 1993;106(961):345.
23. MacCoun R. In what sense (if any) is marijuana a gateway drug? FAS Drug Policy Anal Bull 1998;4.
24. Hall WD. A simplified logic of causal inference. Aust N Z J Psychiatry 1987;21(4):507-513.
25. Hill A. A short textbook of statistics. London: Hodder and Stoughton, 1977.
26. Goode E. Marijuana use and the progression to dangerous drugs. In: Miller LL, ed. Marijuana: effects on human behavior. New York: Academic Press, 1974:p. 303-338.
27. Robins LN. Vietnam veterans' rapid recovery from heroin addiction: a fluke or normal expectation? Addiction 1993;88(8):1041-1054.
28. Cohen S. Drug use: religion and secularization. Am J Psychiatry 1972;129(1):97.
29. Wagner FA, Anthony JC. Into the world of illegal drug use: exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am J Epidemiol 2002;155(10):918-925.
30. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002;156(4):319-327.
31. Bartels M, Hudziak JJ, van den Oord EJ, van Beijsterveldt CE, Tietveld MJ, Moomsma DI. Co-occurrence of aggressive behavior and rule-breaking behavior at age 12: multirater analyses. Behav Genet 2003;33:607-621.
32. Newcomb MD, Bentler PM. Consequences of adolescent drug use: impact on the lives of young adults. Thousand Oaks, CA: Sage, 1988.
33. Jessor R, Jessor SL. Problem behavior and psychosocial development: a longitudinal study of youth. New York: Academic Press, 1977.
34. Osgood DW, Johnston LD, O'Malley PM, Bachman JG. The generality of deviance in late adolescence and early adulthood. Am Sociol Rev 1988;53(1):81-93.
35. Shedler J, Block J. Adolescent drug use and psychological health: a longitudinal inquiry. Am Psychol 1990;45(5):612-630.
36. Brook JS, Cohen P, Whiteman M, Gordon AS. Psychosocial risk factors in the transition from moderate to heavy use or abuse of drugs. In: Glantz MD, ed. Vulnerability to drug abuse. Washington, DC: American Psychological Association, 1992:p. 359-388.
37. Jessor R, Jessor SL. Theory testing in longitudinal research on marijuana use. In: Kandel DB, ed. Longitudinal research on drug use: empirical findings and methodological issues. New York: John Wiley, 1978:p. 41-71.
38. Bailey SL, Flewelling RL, Rachal JV. Predicting continued use of marijuana among adolescents: the relative influence of drug-specific and social context factors. J Health Soc Behav 1992;33(1):51-66.
39. Hawkins JD, Catalane RF, Miller JY. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychol Bull 1992;112(1):64-105.
40. Kandel DB, Davies M. Progression to regular marijuana involvement: phenomenology and risk factors for near-daily use. In: Glantz MD, ed. Vulnerability to drug abuse. Washington, DC: American Psychological Association, 1992:p. 211-253.
41. Kaplan HB, Johnson RJ. Relationships between circumstances surrounding initial illicit drug use and escalation of drug use: moderating effects of gender and early adolescent experiences. In: Glantz MD, Pickens RW, eds. Vulnerability to drug abuse. Washington, DC: American Psychological Association, 1992:p. 299-358.
42. Newcomb MD. Understanding the multidimensional nature of drug use and abuse: the role of consumption, risk factors, and protective factors. In: Glantz MD, ed. Vulnerability to drug abuse. Washington, DC: American Psychological Association, 1992:p. 255-297.
43. Scheier LM, Newcomb MD. Psychosocial predictors of drug use initiation and escalation: an expansion of the multiple risk factors hypothesis using longitudinal data. Contemp Drug Probl 1991;18(1):31-73.
44. O'Donnell JA, Clayton RR. The stepping stone hypothesis -marijuana, heroin, and causality. Chem Depend Behav Biomed Issues 1982;4(3):229-241.
45. Fergusson DM, Horword LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 2002;97:1123-1135.
46. Heath AC. Genetic influences on alcoholism risk: a review of adoption and twin studies. Alcohol Health Res World 1995;19(3):166-171.
47. Kendler KS, Prescott CA. Cannabis use, abuse, and dependence in a population-based sample of female twins. Am J Psychiatry 1998;155(8):1016-1022.
48. Han C, McGue MK, Iacono WG. Lifetime tobacco, alcohol and other substance use in adolescent Minnesota twins: univariate and multivariate behavioral genetic analyses. Addiction 1999;94(7):981-993.
49. True WR, Heath AC, Scherrer JF, Xian H, Lin N, Eisen SA, et al. Interrelationship of genetic and environmental influences on conduct disorder and alcohol and marijuana dependence symptoms. Am J Med Genet 1999;88(4):391 -7.
50. Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 2003;160(4):687-95.
51. Lynskey MT, Heath AC, Bucholz KK, Slutske WS. Escalation of drug use in early-onset cannabis users vs cotwin controls. JAMA-J Am Med Assoc 2003;289(4):427-433.
52. Nahas GG. Keep off the grass. 5th ed. Middlebury, VT: Paul Eriksson, 1990.
53. Walters E. Marijuana: an Australian crisis. Malvern, VIC: E. Walters, 1993.
54. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;276(5321):2048-2050.
55. Gardner EL. Cannabinoid interaction with brain reward systems. In: Nahas G, Sutin KM, Harvey D, Agurell S, eds. Marihuana and medicine. Towa, NJ: Humana Press, 1999:p. 187-205.
56. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999;20:287-294.
57. Ledent CM, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in cbl receptor knockout mice. Science 1999;283:401-404.
58. De Fonseca FR, Carrera MR, Navarro M, Koob GF, Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997;276:2050-2054.
59. Zimmer L, Morgan JP. Marijuana myths, marijuana facts: a review of the scientific evidence. New York: The Lindesmith Center, 1997.
60. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G. Behavioural sensitization after repeated exposure to [delta]9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology (Berl) 2001;158(3):259-266.
61. Lamarque S, Taghzouti K, Simon H. Chronic treatment with [delta] 9-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin: implications for vulnerability to drug addiction. Neuropharmacology 2001;41(1):118-129.
62. Lynskey M. An alternative model is feasible, but the gateway hypothesis has not been invalidated: comments on Morral et al. Addiction 2002;97(12):1505-7.
63. Botvin GJ, Scheier LM, Griffin KW. Preventing the onset and developmental progression of adolescent drug use: implications for the gateway hypothesis. In: Kandel DB, ed. Stages and pathways of drug involvement: examining the gateway hypothesis. New York: Cambridge University Press, 2002:p. 115-138.
64. Gerstein DR, Green LW, eds. Preventing drug abuse: what do we know? Washington, DC: National Academy Press, 1993.
65. Manski CF, Pepper JV, Petrie CV, eds. Informing America's policy on illegal drugs: what we don't know keeps hurting us. Washington, DC: National Academy Press, 2001.
66. Caulkins JP, Rydell CP, Everingham SMS, Chiesa JR, Bushway S. An ounce of prevention, a pound of uncertainty: the cost-effectiveness of school-based drug prevention programs. Santa Monica, CA: Rand Corporation, 1999.